ARVN News and Press, Arvinas Inc. From 05/20/20

NEW HAVEN, Conn., May 20, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that its 2020 Annual Meeting of Stockholders, to be held on Wednesday, June 3, 2020 at...

Gainers:  Applied DNA Sciences (NASDAQ: APDN ) +51% . More news on: Applied DNA Sciences, Inc., Akers Biosciences, Inc., Glory Star New Media Group Holdings Limited, Stocks on the move, , Read more ...

Comstock Resources (NYSE: CRK )  -32%  after pricing 40M-share offering at $5/share. More news on: Comstock Resources, Inc., MacroGenics, Inc., Arvinas, Inc., Stocks on the move, , Read more ...

Arvinas (NASDAQ: ARVN ) is down  16%  premarket on light volume after the release of an abstract on a Phase 1 clinical trial evaluating protein degrader ARV-110 in patients with metastatic treatment-resistant prostate cancer, the first in-human data on a drug with this mechanis...

Arvinas (NASDAQ: ARVN ) down  28.9%  post market, after the company announces  updated safety and initial efficacy data from the dose escalation portion of its Phase 1/2 clinical trial of ARV-110. More news on: Arvinas, Inc., Healthcare stocks news, Read more ...

- Describes the first evidence of clinical benefit for PROTAC® protein degraders, a novel therapeutic modality - - Data to be presented during the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting - NEW HAVEN, Conn., May 13, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc...

Many investors tend to stay away from stocks that are appreciating strongly over time, mostly because of fears of buying too late when the stock is already overvalued. Having some patience when looking for entry prices and being conscious about valuation is very important. However, blindly avo...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

Arvinas (NASDAQ: ARVN ): Q1 GAAP EPS of -$0.56 beats by $0.03 . More news on: Arvinas, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

NEW HAVEN, Conn., April 13, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today provided an update regarding the impact of the COVID-19 pandemic on its overall business conti...